Novartis Sells Majority Stake in Indian Unit Following Strategic Review

Novartis has finalized an agreement to sell a majority stake in its publicly traded Indian subsidiary, concluding a strategic review initiated two years ago. Bloomberg posted on X, highlighting the significance of this decision for the pharmaceutical giant. The move is part of Novartis's broader strategy to streamline operations and focus on core areas of growth. The sale is expected to impact the company's presence in the Indian market, where it has been active for several decades. This decision aligns with Novartis's ongoing efforts to optimize its portfolio and enhance shareholder value. The transaction details, including the buyer and financial specifics, have not been disclosed. Novartis's strategic review aimed to evaluate its business segments and identify opportunities for divestment or restructuring. The company has been actively reshaping its global operations to concentrate on innovative medicines and cutting-edge therapies. This latest development underscores Novartis's commitment to refining its business model and adapting to changing market dynamics.